FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128767964> ?p ?o ?g. }

• W3128767964 endingPage "1052" @default.
• W3128767964 startingPage "1044" @default.
• W3128767964 abstract "Purpose Decreased peripheral lymphocyte counts are associated with survival after radiation therapy (RT) in several solid tumors, although they appear late during or after the radiation course and often correlate with other clinical factors. Here we investigate if absolute lymphocyte counts (ALCs) are independently associated with recurrence in pediatric medulloblastoma early during RT. Methods and Materials We assessed 202 patients with medulloblastoma treated between 2000 and 2016 and analyzed ALC throughout therapy, focusing on both early markers (ALC during week 1 – ALCwk1; grade 3+ Lymphopenia during week 2 – Lymphopeniawk2) and late markers (ALC nadir). Uni- and multivariable regressions were used to assess association of clinical and treatment variables with ALC and of ALC with recurrence. Results Thirty-six recurrences were observed, with a median time to recurrence of 1.6 years (range, 0.2-10.3) and 7.1 years median follow-up. ALC during RT was associated with induction chemotherapy (P < .001), concurrent carboplatin (P = .009), age (P = .01), and high-risk status (P = .05). On univariable analysis, high-risk disease (hazard ratio = 2.0 [1.06-3.9]; P = .03) and M stage≥1 (hazard ratio = 2.2 [1.1-4.4]) were associated with recurrence risk, as was lower ALC early during RT (ALCwk1, hazard ratio = 0.28 [0.12-0.65]; P = .003; Lymphopeniawk2, hazard ratio = 2.27 [1.1-4.6]; P = .02). Neither baseline ALC nor nadir correlated with outcome. These associations persisted when excluding carboplatin and pre-RT chemotherapy patients, and in the multivariable analysis accounting for confounders lymphocyte counts remained significant (ALCwk1, hazard-ratio = 0.23 [0.09-0.57]; P = .002; Lymphopeniawk2, hazard-ratio = 2.3 [1.1-4.8]; P = .03). Conclusions ALC during weeks 1 and 2 of RT was associated with recurrence, and low ALC is an independent prognostic factor in medulloblastoma. Strategies to mitigate the risk of radiation-induced lymphopenia should be considered. Decreased peripheral lymphocyte counts are associated with survival after radiation therapy (RT) in several solid tumors, although they appear late during or after the radiation course and often correlate with other clinical factors. Here we investigate if absolute lymphocyte counts (ALCs) are independently associated with recurrence in pediatric medulloblastoma early during RT. We assessed 202 patients with medulloblastoma treated between 2000 and 2016 and analyzed ALC throughout therapy, focusing on both early markers (ALC during week 1 – ALCwk1; grade 3+ Lymphopenia during week 2 – Lymphopeniawk2) and late markers (ALC nadir). Uni- and multivariable regressions were used to assess association of clinical and treatment variables with ALC and of ALC with recurrence. Thirty-six recurrences were observed, with a median time to recurrence of 1.6 years (range, 0.2-10.3) and 7.1 years median follow-up. ALC during RT was associated with induction chemotherapy (P < .001), concurrent carboplatin (P = .009), age (P = .01), and high-risk status (P = .05). On univariable analysis, high-risk disease (hazard ratio = 2.0 [1.06-3.9]; P = .03) and M stage≥1 (hazard ratio = 2.2 [1.1-4.4]) were associated with recurrence risk, as was lower ALC early during RT (ALCwk1, hazard ratio = 0.28 [0.12-0.65]; P = .003; Lymphopeniawk2, hazard ratio = 2.27 [1.1-4.6]; P = .02). Neither baseline ALC nor nadir correlated with outcome. These associations persisted when excluding carboplatin and pre-RT chemotherapy patients, and in the multivariable analysis accounting for confounders lymphocyte counts remained significant (ALCwk1, hazard-ratio = 0.23 [0.09-0.57]; P = .002; Lymphopeniawk2, hazard-ratio = 2.3 [1.1-4.8]; P = .03). ALC during weeks 1 and 2 of RT was associated with recurrence, and low ALC is an independent prognostic factor in medulloblastoma. Strategies to mitigate the risk of radiation-induced lymphopenia should be considered." @default.
• W3128767964 created "2021-02-15" @default.
• W3128767964 creator A5000955309 @default.
• W3128767964 creator A5001528733 @default.
• W3128767964 creator A5001841078 @default.
• W3128767964 creator A5008119029 @default.
• W3128767964 creator A5014884181 @default.
• W3128767964 creator A5023651604 @default.
• W3128767964 creator A5032331306 @default.
• W3128767964 creator A5048643503 @default.
• W3128767964 creator A5054954036 @default.
• W3128767964 creator A5056658906 @default.
• W3128767964 creator A5068419309 @default.
• W3128767964 creator A5072375420 @default.
• W3128767964 creator A5072499473 @default.
• W3128767964 creator A5075301401 @default.
• W3128767964 creator A5080426159 @default.
• W3128767964 creator A5084038131 @default.
• W3128767964 date "2021-07-01" @default.
• W3128767964 modified "2023-10-18" @default.
• W3128767964 title "Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma" @default.
• W3128767964 cites W1757492577 @default.
• W3128767964 cites W1778834185 @default.
• W3128767964 cites W1967084952 @default.
• W3128767964 cites W1991493210 @default.
• W3128767964 cites W2023482364 @default.
• W3128767964 cites W2039677900 @default.
• W3128767964 cites W2045711626 @default.
• W3128767964 cites W2047866259 @default.
• W3128767964 cites W2048665768 @default.
• W3128767964 cites W2052775869 @default.
• W3128767964 cites W2111900445 @default.
• W3128767964 cites W2117482566 @default.
• W3128767964 cites W2117878645 @default.
• W3128767964 cites W2121971059 @default.
• W3128767964 cites W2127643721 @default.
• W3128767964 cites W2133739473 @default.
• W3128767964 cites W2134501934 @default.
• W3128767964 cites W2137289789 @default.
• W3128767964 cites W2139758621 @default.
• W3128767964 cites W2142560661 @default.
• W3128767964 cites W2150794759 @default.
• W3128767964 cites W2153435200 @default.
• W3128767964 cites W2156074429 @default.
• W3128767964 cites W2160607660 @default.
• W3128767964 cites W2262418885 @default.
• W3128767964 cites W2263581080 @default.
• W3128767964 cites W2366536035 @default.
• W3128767964 cites W2560232895 @default.
• W3128767964 cites W2621240220 @default.
• W3128767964 cites W2621243763 @default.
• W3128767964 cites W2744419411 @default.
• W3128767964 cites W2773643507 @default.
• W3128767964 cites W2794162546 @default.
• W3128767964 cites W2797600049 @default.
• W3128767964 cites W2802109771 @default.
• W3128767964 cites W2805273538 @default.
• W3128767964 cites W2808607186 @default.
• W3128767964 cites W2891915572 @default.
• W3128767964 cites W2914445643 @default.
• W3128767964 cites W2942466014 @default.
• W3128767964 cites W2954542121 @default.
• W3128767964 cites W3011819195 @default.
• W3128767964 cites W3049175319 @default.
• W3128767964 cites W3096077542 @default.
• W3128767964 cites W4252935772 @default.
• W3128767964 doi "https://doi.org/10.1016/j.ijrobp.2021.01.035" @default.
• W3128767964 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8238781" @default.
• W3128767964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33556478" @default.
• W3128767964 hasPublicationYear "2021" @default.
• W3128767964 type Work @default.
• W3128767964 sameAs 3128767964 @default.
• W3128767964 citedByCount "7" @default.
• W3128767964 countsByYear W31287679642021 @default.
• W3128767964 countsByYear W31287679642022 @default.
• W3128767964 countsByYear W31287679642023 @default.
• W3128767964 crossrefType "journal-article" @default.
• W3128767964 hasAuthorship W3128767964A5000955309 @default.
• W3128767964 hasAuthorship W3128767964A5001528733 @default.
• W3128767964 hasAuthorship W3128767964A5001841078 @default.
• W3128767964 hasAuthorship W3128767964A5008119029 @default.
• W3128767964 hasAuthorship W3128767964A5014884181 @default.
• W3128767964 hasAuthorship W3128767964A5023651604 @default.
• W3128767964 hasAuthorship W3128767964A5032331306 @default.
• W3128767964 hasAuthorship W3128767964A5048643503 @default.
• W3128767964 hasAuthorship W3128767964A5054954036 @default.
• W3128767964 hasAuthorship W3128767964A5056658906 @default.
• W3128767964 hasAuthorship W3128767964A5068419309 @default.
• W3128767964 hasAuthorship W3128767964A5072375420 @default.
• W3128767964 hasAuthorship W3128767964A5072499473 @default.
• W3128767964 hasAuthorship W3128767964A5075301401 @default.
• W3128767964 hasAuthorship W3128767964A5080426159 @default.
• W3128767964 hasAuthorship W3128767964A5084038131 @default.
• W3128767964 hasBestOaLocation W31287679642 @default.
• W3128767964 hasConcept C126322002 @default.
• W3128767964 hasConcept C142724271 @default.
• W3128767964 hasConcept C143998085 @default.
• W3128767964 hasConcept C207103383 @default.

• next